+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07578363

Evaluation of Apraclonidine 0.125% Ophthalmic Solution Compared to Placebo for Reducing Eye Redness in Adults

Led by Alcon Research · Updated on 2026-10-16

178

Participants Needed

5

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of an investigational eye drop called Apraclonidine Ophthalmic Solution 0.125% in adults experiencing redness caused by minor eye irritations. This Phase 3 study compares this solution to an inactive placebo Vehicle to assess its ability to reduce ocular redness. The trial is randomized and double-blinded, ensuring unbiased results. Participants will receive a single dose of the study treatment in each eye on the first day at the clinic. Then, they will self-administer one drop in each eye twice daily at home for about eight weeks, with the final dose given in the clinic on Day 56. Following a one-week break from treatment, participants return for a final visit on Day 63. Eye redness is measured at specific times before and after dosing to track changes. During the study, participants attend six clinic visits over approximately 10 weeks. Redness is assessed at multiple time points on Day 1 and during follow-up visits. Researchers monitor safety, including any adverse effects, and evaluate how the eye drops affect redness over time. The trial aims to provide detailed information on the treatments impact on ocular redness and participant safety throughout the study period.

CONDITIONS

Brief Title

An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults

Research Team

A

Alcon Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here